Abstract: What is described is a peptide which consists of 7-20, especially 7-17, adjacent amino acids and comprises the hexamer TX1EX2X3E where X1, X2 and X3 may be any natural or unnatural amino acid, where the peptide does not have any TNF receptor binding activity and is cyclized, for use for the treatment and avoidance of the pulmonary form of altitude sickness.
Type:
Grant
Filed:
June 19, 2013
Date of Patent:
October 31, 2017
Assignee:
APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH
Inventors:
Bernhard Fischer, Rudolf Lucas, Hendrik Fischer
Abstract: Hydrogels comprising a macromolecular matrix and water may be used for aesthetic fillers, for example, dermal fillers. The macromolecular matrix may include a crosslinked combination of hyaluronic acid and collagen.
Type:
Grant
Filed:
May 31, 2017
Date of Patent:
October 24, 2017
Assignee:
Allergan, Inc.
Inventors:
Xiaojie Yu, Nicholas J. Manesis, Jacob Pollock
Abstract: A formulation and method are provided for treating wounds by promoting healing and tissue repair and/or regeneration therein. The formulation is a topically administrable selectively flowable colloidal suspension that contains a tropocollagen, at least one adjuvant effective to enhance the capability of the formulation or the tropocollagen to promote tissue repair and regeneration following topical administration to a wound, and a physiologically acceptable carrier or excipient. At least 50% of the tropocollagen is composed of renatured tropocollagen, generally renatured atelopeptide tropocollagen. Methods for using the formulation to heal a wound and effect tissue repair and/or regeneration therein are also provided.
Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
Type:
Grant
Filed:
August 24, 2016
Date of Patent:
October 10, 2017
Assignee:
ENDOCYTE, INC.
Inventors:
Iontcho Radoslavov Vlahov, Joseph Anand Reddy, Alicia Bloomfield, Ryan Dorton, Melissa Nelson, Marilynn Vetzel, Christopher Paul Leamon
Abstract: Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component.
Type:
Grant
Filed:
April 24, 2017
Date of Patent:
October 10, 2017
Assignee:
Allergan, Inc.
Inventors:
Jacob F. Pollock, Lauren E. Kokai, Cunqi Cui, Xiaojie Yu, Dennis E. Van Epps, Darin J. Messina
Abstract: The present invention relates to inhibitors of Nox1-dependent reactive oxygen species production and their use in the treatment of disorders associated with reactive oxygen species, such as hypertension and cancer.
Type:
Grant
Filed:
October 9, 2015
Date of Patent:
September 26, 2017
Assignee:
UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Inventors:
Daniel J. Ranayhossaini, Patrick Joseph Pagano
Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.
Type:
Grant
Filed:
April 11, 2016
Date of Patent:
September 19, 2017
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Ira H. Pastan, Ronit Mazor, Masanori Onda, Aaron Vassall, Richard Beers, Jaime Eberle, Wenhai Liu
Abstract: The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.
Type:
Grant
Filed:
October 6, 2016
Date of Patent:
September 19, 2017
Assignee:
Hanmi Science Co., Ltd.
Inventors:
Sung Youb Jung, Myung Hyun Jang, Ling Ai Shen, Young Kyung Park, Young Jin Park, Se Chang Kwon
Abstract: The invention relates to novel stable and protracted GLP-1/glucagon receptor co-agonists, to the use of said peptides in therapy, to methods of treatment comprising administration of said peptides to patients, and to the use of said peptides in the manufacture of medicaments.
Type:
Grant
Filed:
June 10, 2016
Date of Patent:
September 5, 2017
Assignee:
Novo Nordisk A/S
Inventors:
Ulrich Sensfuss, Thomas Kruse, Jesper F. Lau
Abstract: An anti-tumor polypeptide, having an amino acid sequence represented by FPGSDRF (SEQ ID NO: 15), X-FPGSDRF (SEQ ID NO: 16), FPGSDRF-Z (SEQ ID NO: 17), or X-FPGSDRF-Z (SEQ ID NO: 18) is disclosed. The various capital letters denote amino acids: F: phenylalanine; P: proline; G: glycine; D: aspartic acid; R: arginine; S is a phosphorylated serine residue, X and Z are an amino acid residue or an amino acid sequence, respectively, X is one selected from the group consisting of F, (R)9 (SEQ ID NO: 19), (R)9-F (SEQ ID NO: 20), 6-aminocaproic acid, 6-aminocaproic acid-F, 6-aminocaproic acid-(R)9 (SEQ ID NO: 21), and 6-aminocaproic acid-(R)9-F (SEQ ID NO: 22), Z is one selected from the group consisting of A, (G)n-RGD (SEQ ID NO: 23), and A-(G)n-RGD (SEQ ID NO: 24); and n is an integer greater than or equal to 0.
Type:
Grant
Filed:
November 16, 2015
Date of Patent:
August 29, 2017
Assignee:
NANJING MEDICAL UNIVERSITY
Inventors:
Jianwei Zhou, Jin Xu, Xuan Li, Aiping Li
Abstract: The invention provides peptides and analogs of INGAP and HIP peptides. The peptides and analogs can be used in methods for treating various diseases and conditions. Such diseases and conditions can include impaired pancreatic function, treating a metabolic disease, for example, diabetes, both type 1 and type 2 diabetes, islets induction, expansion and proliferation for transplantation, promoting neuroprotection or nerve regeneration, promoting liver regeneration or inhibiting inflammation.
Abstract: Therapies and compositions for reducing collagen synthesis in mammalian cells and tissues wherein the targets are scleraxis, scleraxis-binding sites, receptor-regulated Smads, and/or binding sites for receptor-regulated Smads whereby synergistic interactions between scleraxis proteins and receptor-regulated Smads are reduced, inhibited, interfered with, stopped, and/or prevented thereby reducing, inhibiting and/or interfering with the activation of collagen 1?2 promoter thereby inhibiting collagen production in mammalian cells and tissues. Alternatively, the therapies and compositions may reduce, inhibit, interfere with, stop, and/or prevent binding of the collagen 1?2 promoter to DNA thereby inhibiting expression of the collagen 1?2 gene in mammalian cells and tissues.
Abstract: The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.
Type:
Grant
Filed:
June 15, 2012
Date of Patent:
August 15, 2017
Assignee:
Hanmi Science Co., Ltd.
Inventors:
Sung Youb Jung, Dae Jin Kim, Sung Hee Park, Young Eun Woo, In Young Choi, Se Chang Kwon
Abstract: The present disclosure provides peptides and constructs that inhibit mitochondrial fission, and compositions comprising the peptides or constructs. The present disclosure provides methods of reducing abnormal mitochondrial fission in a cell. Also provided are methods for designing and validating mitochondrial fission inhibitor constructs and peptides, including but not limited to, evaluating the effects of the constructs and peptides on binding of dynamin-1-related protein (Drp1) GTPase activity, Drp1 to mitochondrial fission 1 protein (Fis1), reduction of mitochondrial damage, reduction in cell death, inhibition of mitochondrial fragmentation in a cell under pathological conditions, and reduced loss of neurites in primary dopaminergic neurons in a Parkinsonism cell culture.
Type:
Grant
Filed:
January 5, 2016
Date of Patent:
August 15, 2017
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of FDYDWY (SEQ ID NO: 2), SFSQNKSVHSFDYDWYNVSDQADLKN (SEQ ID NO: 3) or CSFSQNKSVHSFDYDWYNVSDQADLKNC (SEQ ID NO: 1), or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.
Type:
Grant
Filed:
May 29, 2015
Date of Patent:
August 15, 2017
Assignee:
TEL HASHOMER MEDICAL RESEARCH, INFRASTRUCTURE AND SERVICES LTD.
Abstract: The invention relates to novel pharmaceutically-useful peptides, in particular cyclic peptides that are agonists of the AngII type 2 receptor (AT2 receptor). The invention further relates to the use of such peptides as medicaments, to pharmaceutical compositions containing them, and to their production.
Type:
Grant
Filed:
January 29, 2016
Date of Patent:
July 18, 2017
Assignee:
LANTHIOPEP B.V.
Inventors:
Louwe De Vries, Sieger Adriaan Nelemans, Rick Rinck, Antonius Jacobus Marinus Roks, Gert Nikolaas Moll
Abstract: Use of a subcutaneously administered dose of between about 1.0 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
Type:
Grant
Filed:
May 5, 2015
Date of Patent:
July 11, 2017
Assignee:
Palatin Technologies, Inc.
Inventors:
Carl Spana, Robert Jordan, Jeffrey D. Edelson
Abstract: A conjugate of water soluble polymer-amino acid oligopeptide-drug of Formula (I) below and a pharmaceutical composition comprising the conjugate are provided. In the conjugate, P is a water soluble polymer; X is a linking group, wherein the linking group links P and A1; each of A1, A2 and A3 is independently same or different amino acid residue or amino acid analogue residue; each of D1 and D2 is independently same or different drug molecule residue; a is 0 or 1; b is an integer of 2-12; c is an integer of 0-7; d is 0 or 1. The conjugate could improve drug load capacity, water solubility, stability and activity of the drug.
Abstract: Compositions comprising a protein or isolated peptide, and methods using the same for preventing, dispersing or detaching a biofilm, are disclosed.
Type:
Grant
Filed:
November 24, 2015
Date of Patent:
July 11, 2017
Assignee:
Hutchison Biofilm Medical Solutions Ltd.
Abstract: The present invention relates to an improved macromolecule transduction domain (MTD), which facilitates permeating the cell membrane of a biologically active molecule, having enhanced cell permeability. Specifically, an improved MTD according to the present invention, compared to an existing MTD, can transmit various types of biologically active molecule from inside the body and inside a test tube more effectively, and thus can be effectively used in a method to genetically alter a biologically active molecule so as to have cell permeability or in a method to transport a biologically active molecule into a cell, or the like. Additionally, the improved MTD can be very useful in development of new drugs and incrementally modified drugs as uses of the improved MTD are possible in drug delivery systems, recombinant protein vaccines or DNA/RNA therapeutic agents, gene or protein therapies, and pharmacologically or medically useful protein production or medical, pharmacological and pharmaceutical compositions.
Type:
Grant
Filed:
January 15, 2016
Date of Patent:
July 4, 2017
Assignee:
PROCELL THERAPEUTICS INC.
Inventors:
Ki Deok Shin, Kang Jin Lee, Sunny Lim, Byung Kyu Lee, Jong Rae Kim